U.S. markets open in 7 hours 16 minutes

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.46+0.36 (+3.24%)
At close: 4:00PM EST

Poseida Therapeutics, Inc.

9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100
http://www.poseida.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees186

Key Executives

NameTitlePayExercisedYear Born
Dr. Eric M. OstertagCEO, Sec. & Director703.16kN/A1973
Mr. Kerry D. IngallsChief Operating Officer384.98kN/A1962
Dr. Matthew A. SpearChief Medical Officer597.94kN/A1967
Mr. Mark J. GergenPres, Chief Bus. Officer & DirectorN/AN/A1963
Ms. Johanna M. Mylet CPASr. VP of Fin.N/AN/A1987
Mr. Harry J. LeonhardtGen. Counsel ,Chief Compliance Officer & Corp. Sec.N/AN/A1957
Ms. Kristin MartinChief HR OfficerN/AN/AN/A
Devon ShedlockSr. VP of R&DN/AN/AN/A
Mr. Jeff KnightSr. VP of Global OperationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Corporate Governance

Poseida Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.